Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis

Authors: Martín E Rabassa, María V Croce, Adrián Pereyra, Amada Segal-Eiras

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

HNSCC progression to adjacent tissue and nodes may be mediated by altered glycoproteins and glycolipids such as MUC1 mucin. This report constitutes a detailed statistical study about MUC1 expression and anti-MUC1 immune responses in relation to different clinical and pathological parameters which may be useful to develop new anti HNSCC therapeutic strategies.

Patients and methods

Fifty three pre treatment HNSCC patients were included: 26 (49.1%) bearing oral cavity tumors, 17 (32.1%) localized in the larynx and 10 (18.8%) in the pharynx. Three patients (5.7%) were at stage I, 5 (9.4%) stage II, 15 (28.3%) stage III and 30 (56.6%) at stage IV. MUC1 tumor expression was studied by immunohistochemistry employing two anti-MUC1 antibodies: CT33, anti cytoplasmic tail MUC1 polyclonal antibody (Ab) and C595 anti-peptidic core MUC1 monoclonal antibody. Serum levels of MUC1 and free anti-MUC1 antibodies were detected by ELISA and circulating immune complexes (CIC) by precipitation in polyethylene glycol (PEG) 3.5%; MUC1 isolation from circulating immune complexes was performed by protein A-sepharose CL-4B affinity chromatography followed by SDS-PAGE and Western blot. Statistical analysis consisted in Multivariate Principal Component Analysis (PCA); ANOVA test (Tukey's test) was employed to find differences among groups; nonparametrical correlations (Kendall's Tau) were applied when necessary. Statistical significance was set to p < 0.05 in all cases.

Results

MUC1 cytoplasmic tail was detected in 40/50 (80%) and MUC1 protein core in 9/50 (18%) samples while serum MUC1 levels were elevated in 8/53 (15%) patients. A significant statistical correlation was found between MUC1 serum levels and anti-MUC1 IgG free antibodies, while a negative correlation between MUC1 serum levels and anti-MUC1 IgM free antibodies was found. Circulating immune complexes were elevated in 16/53 (30%) samples and were also statistically associated with advanced tumor stage. MUC1 was identified as an antigenic component of IgG circulating immune complexes. Moreover, poorly differentiated tumors were inversely correlated with tumor and serum MUC1 detection and positively correlated with node involvement and tumor mass.

Conclusion

Possibly, tumor cells produce MUC1 mucin which is liberated to the circulation and captured by IgG antibodies forming MUC1-IgG-CIC. Another interesting conclusion is that poorly differentiated tumors are inversely correlated with tumor and serum MUC1 detection.
Appendix
Available only for authorised users
Literature
1.
Döbrössy L: Epidemiology of head and neck cancer: magnitude of the problem. Cancer and Metastasis Reviews. 2005, 24: 9-17. 10.1007/s10555-005-5044-4.CrossRefPubMed
2.
Shermann CD: Cancer of the head and neck. Manual of Clinical Oncology. 1990, UICC, SpringerCrossRef
3.
4.
Stewart B, Kleihues P, editors: World cancer report. 2003, Lyon: IARC Press
5.
6.
Croce MV, Price MR, Segal-Eiras A: Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma. Pathol Oncol Res. 2000, 6: 93-9.CrossRefPubMed
7.
Croce MV, Rabassa ME, Price MR, Segal-Eiras A: MUC1 mucin and carbohydrate associated antigens as tumor markers in head and neck squamous cell carcinoma. Pathol Oncol Res. 2001, 7: 284-91.CrossRefPubMed
8.
Croce MV, Rabassa ME, Pereyra A, Segal-Eiras A: Influence of sialic acid removal on MUC1 antigenic reactivity in head and neck carcinoma. Pathol Oncol Res. 2005, 11: 74-81.CrossRefPubMed
9.
Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia. 2002, 7: 209-21. 10.1023/A:1020360121451.CrossRefPubMed
10.
Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 1994, 54: 2856-60.PubMed
11.
von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, Litvinov SV, van Kamp GJ, Meijer S, Vermorken J, Hilgers J: Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer. 1996, 32A: 1325-31. 10.1016/0959-8049(96)00048-2.CrossRefPubMed
12.
Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A: Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat. 2003, 81: 195-207. 10.1023/A:1026110417294.CrossRefPubMed
13.
Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, Symonds IM, Clarke AJ, Chan WC, Baldwin RW: C595 – a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer. 1990, 61: 681-6.CrossRefPubMedPubMedCentral
14.
Croce MV, Isla-Larrain MT, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol. 2006, 21: 849-55.PubMed
15.
Croce MV, Isla-Larrain MT, Rua CE, Rabassa ME, Gendler SJ, Segal-Eiras A: Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer. J Histochem Cytochem. 2003, 51: 781-8.CrossRefPubMed
16.
Feickert H, Anger B, Cordón-Cardo C, Lloyd K: Cell-surface antigens of human tumors detected by mouse monoclonal antibodies: definition of blood-group- and non-blood-group-related antigenic systems. Int J Cancer. 1990, 46: 1007-1013.CrossRefPubMed
17.
Renkonen J, Paavonen T, Renkonen R: Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer. 1997, 74: 296-300. 10.1002/(SICI)1097-0215(19970620)74:3<296::AID-IJC11>3.0.CO;2-A.CrossRefPubMed
18.
Luna-More S, Rius F, Weil B, Jimenez A, Bautista MD, Perez-Mellado A: EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. Pathol Res Pract. 2001, 197: 419-25. 10.1078/0344-0338-00055.CrossRefPubMed
19.
Croce MV, Price MR, Segal-Eiras A: Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum. Cancer Immunol Immunother. 1995, 40: 132-7. 10.1007/BF01520296.CrossRefPubMed
20.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-5. 10.1038/227680a0.CrossRefPubMed
21.
Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979, 76: 4350-4. 10.1073/pnas.76.9.4350.CrossRefPubMedPubMedCentral
22.
Von Mensdorff-Pouilly S, Gouretvich MM, Kenemans P: An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol. 1989, 186-195.
23.
Croce MV, Isla-Larrain MT, Capafons A, Price MR, Segal-Eiras A: Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat. 2001, 69: 1-11. 10.1023/A:1012220902991.CrossRefPubMed
24.
Wang H, Lillehoj EP, Kim KC: Identification of four sites of stimulated tyrosine phosphorylation in the MUC1 cytoplasmic tail. Biochem Biophys Res Commun. 2003, 310: 341-6. 10.1016/j.bbrc.2003.09.030.CrossRefPubMed
25.
Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH: Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett. 1994, 356: 130-6. 10.1016/0014-5793(94)01251-2.CrossRefPubMed
26.
Pandey P, Kharbanda S, Kufe D: Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res. 1995, 55: 4000-3.PubMed
27.
Yamamoto M, Bharti A, Li Y, Kufe D: Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem. 1997, 272: 12492-4. 10.1074/jbc.272.19.12492.CrossRefPubMed
28.
Schroeder JA, Thompson MC, Gardner MM, Gendler SJ: Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem. 2001, 276: 13057-64. 10.1074/jbc.M011248200.CrossRefPubMed
29.
Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky I, Kotkes P, Weiss M, Lathe R, Dion AS, Keydar I: Human epithelial tumor antigen cDNA sequences – differential splicing may generate multiple protein forms. Eur J Biochem. 1990, 189: 463-73. 10.1111/j.1432-1033.1990.tb15511.x.CrossRefPubMed
30.
Zrihan-Licht S, Vos HL, Baruch A, Elroy-Stein O, Sagiv D, Keydar I, Hilkens J, Wreschner DH: Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. Eur J Biochem. 1994, 224: 787-95. 10.1111/j.1432-1033.1994.00787.x.CrossRefPubMed
31.
Obermair A, Schmid BC, Stimpfl M, Fasching B, Preyer O, Leodolter S, Crandon AJ, Zeillinger R: Novel MUC1 splice variants are expressed in cervical carcinoma. Gynecol Oncol. 2001, 83: 343-7. 10.1006/gyno.2001.6396.CrossRefPubMed
32.
Agrawal B, Reddish MA, Longenecker BM: In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol. 1996, 157: 2089-95.PubMed
33.
Petrarca C, Rughetti A, Rahimi H, D'Agostini F, Turchi V, Apollonj Ghetti C, Scambia G, Frati L, Nuti M: Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region. Eur J Cancer. 1996, 32A: 2155-63. 10.1016/S0959-8049(96)00254-7.CrossRefPubMed
34.
Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y: Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer. 2003, 103: 97-100. 10.1002/ijc.10801.CrossRefPubMed
35.
von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000, 18: 574-83.PubMed
36.
Vlock DR, Scalise D, Schwartz DR, Richter DE, Krause CJ, Baker SR, Carey TE: Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration. Cancer Res. 1989, 49: 1361-5.PubMed
37.
Yamanaka N, Himi T, Harabuchi Y, Hoki K, Kataura A: Soluble immune complexes and squamous cell carcinoma-related antigens in patients with head and neck cancer. Cancer. 1988, 62: 1932-8. 10.1002/1097-0142(19881101)62:9<1932::AID-CNCR2820620911>3.0.CO;2-A.CrossRefPubMed
38.
Wolf GT, Wolfe RA: Circulating immune complexes in patients with nasopharyngeal carcinoma. Laryngoscope. 1990, 100: 302-8.PubMed
39.
Das TK, Aziz M, Rattan A, Sherwani R: Prognostic significance of circulating immune complexes in malignant tumours of head and neck. J Indian Med Assoc. 1995, 93: 3-7.PubMed
40.
Litvinov SV, Hilkens J: The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem. 1993, 268: 21364-71.PubMed
41.
Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem. 1990, 265: 5573-8.PubMed
42.
Williams CJ, Wreschner DH, Tanaka A, Tsarfaty I, Keydar I, Dion AS: Multiple protein forms of the human breast tumor-associated epithelial membrane antigen (EMA) are generated by alternative splicing and induced by hormonal stimulation. Biochem Biophys Res Commun. 1990, 170: 1331-8. 10.1016/0006-291X(90)90540-4.CrossRefPubMed
43.
Levitin F, Stern O, Weiss M, Gil-Henn C, Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB, Wreschner DH: The MUC1 SEA module is a self-cleaving domain. J Biol Chem. 2005, 280: 33374-86. 10.1074/jbc.M506047200.CrossRefPubMed
44.
Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA: Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem. 2003, 278: 38029-39. 10.1074/jbc.M304333200.CrossRefPubMed
Metadata
Title
MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis
Authors
Martín E Rabassa
María V Croce
Adrián Pereyra
Amada Segal-Eiras
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-253

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Case report

Carcinosarcoma of monoclonal origin arising in a dermoid cyst of ovary: a case report

Research article

Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population

Research article

CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum

Research article

Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival

Research article

Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer

Research article

Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits